P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

Bibliographic Details
Main Authors:	W. Barcellini, R. F. Grace, H. Al-Samkari, A. Glenthøj, J. A. Rothman, M. Morado Arias, D. M. Layton, O. Andres, M. DiBacco, P. Hawkins, M. P. Judge, F. Tai, J. Morales-Arias, V. Beynon, E. J. van Beers
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000849048.44424.2a

Similar Items

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
by: Hanny Al-Samkari, et al.
Published: (2023-08-01)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
by: R. F. Grace, et al.
Published: (2022-06-01)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
by: Eduard van Beers, et al.
Published: (2023-08-01)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
by: E. J. van Beers, et al.
Published: (2022-06-01)

Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment
by: Hanny Al-Samkari, et al.
Published: (2023-09-01)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
by: H. Al-Samkari, et al.
Published: (2022-06-01)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
by: Rachael F. Grace, et al.
Published: (2023-08-01)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
by: K. H. Kuo, et al.
Published: (2022-06-01)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
by: H. Al-Samkari, et al.
Published: (2022-06-01)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
by: R. F. Grace, et al.
Published: (2022-06-01)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
by: R. F. Grace, et al.
Published: (2022-06-01)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K Kuo, et al.
Published: (2022-01-01)

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K. H. M. Kuo, et al.
Published: (2022-06-01)

Mitapivat: New dawn in pyruvate kinase deficiency and beyond
by: Ritika Khurana, et al.
Published: (2024-06-01)

Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
by: Myrthe J. vanDijk, et al.
Published: (2024-06-01)

The variable manifestations of disease in pyruvate kinase deficiency and their management
by: Hanny Al-Samkari, et al.
Published: (2020-03-01)

High Resolution Crystal Structure of the Pyruvate Kinase Tetramer in Complex with the Allosteric Activator Mitapivat/AG-348
by: Xiao Han, et al.
Published: (2024-05-01)

P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
by: Dagmar Pospíŝilová, et al.
Published: (2023-08-01)

PB2247: PHARMACOKINETIC MODELING AND SIMULATION TO SUPPORT MITAPIVAT DOSE SELECTION USED IN PEDIATRIC PHASE III STUDIES
by: O. Yin, et al.
Published: (2022-06-01)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M.J. van Dijk, et al.
Published: (2023-04-01)

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice
by: Alessandro Mattè, et al.
Published: (2023-02-01)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
by: Myrthe van Dijk, et al.
Published: (2023-08-01)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M. J. van Dijk, et al.
Published: (2022-06-01)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: VAN DIJK M., et al.
Published: (2022-08-01)

Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease
by: Angelo D’Alessandro, et al.
Published: (2024-03-01)

AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes
by: Minke A.E. Rab, et al.
Published: (2020-01-01)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K Kuo, et al.
Published: (2022-01-01)

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: KH Kuo, et al.
Published: (2021-10-01)

P107: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE
by: J Howard, et al.
Published: (2022-01-01)

The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
by: Yan Yan, et al.
Published: (2023-03-01)

Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias – pilot study protocol
by: Niels Vejlstrup, et al.
Published: (2024-07-01)

Laser cutting applications in product design
by: DiBacco, John, 1976-
Published: (2005)

ENERGIZE: A GLOBAL PHASE 3 STUDY OF MITAPIVAT DEMONSTRATING EFFICACY AND SAFETY IN ADULTS WITH ALPHA- OR BETA-NON–TRANSFUSION-DEPENDENT THALASSEMIA
by: AT Taher, et al.
Published: (2024-10-01)

S273: EVIDENCE OF NONINFERIORITY OF MITAPIVAT VERSUS SPLENECTOMY IN MURINE HEREDITARY SPHEROCYTOSIS
by: A. Matte’, et al.
Published: (2022-06-01)

P1562: CHARACTERIZING IRON OVERLOAD BY AGE IN PATIENTS DIAGNOSED WITH PYRUVATE KINASE DEFICIENCY – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
by: P. Bianchi, et al.
Published: (2022-06-01)

IMPROVEMENTS IN FATIGUE AND 6-MINUTE WALK TEST IN ADULTS WITH ALPHA- OR BETA-NON–TRANSFUSION-DEPENDENT THALASSEMIA: THE PHASE 3 ENERGIZE TRIAL OF MITAPIVAT
by: KH Kuo, et al.
Published: (2024-10-01)

Suárez (1548˗1617) et Grotius (1583−1645)
by: Jean‑Paul Coujou
Published: (2024-10-01)

INDIGENOUS REVOLT, THE CREATION OF GOVERNMENT GENERAL AND THE 1548 REGIMENT
by: Maria Hilda Baqueiro Paraiso
Published: (2011-06-01)

Pyruvate Kinase Deficiency: Current Challenges and Future Prospects
by: Fattizzo B, et al.
Published: (2022-09-01)

Aprendizaje cooperativo para las habilidades cognoscitivas
by: Lucia Di'Bacco, et al.
Published: (2015-01-01)